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Abstract
Background: Benign prostatic hyperplasia (BPH) is the commonest disease of the urinary tract
afflicting the ageing male and is the commonest neoplastic disease in men aged 50 years and above.
Transurethral prostatectomy (TURP) is the ultimate treatment of choice for benign prostatic
hyperplasia (BPH) due mainly to the preference of minimally invasive surgery, long term relief of
symptoms and cost effectiveness. It is however not available to the majority of Nigerians in need
of prostatic surgery in Public Health Institutions.
Methods:  The records of patients who underwent prostatectomy in Aminu Kano Teaching
Hospital, over the period June 2001 to July 2007 were examined. The bio data of patients and
laboratory investigations performed were retrieved.
Results: Five Hundred and forty two patients were operated upon, out of which 40 were excluded
due to open prostatectomy (22 patients), bladder neck stenosis (16 patients) or bladder tumour
around the trigon (2 patients). The age range of the patients was 47–110 years with a mean of 67.2
years. 289 patients (80.1%) had urethral catheter in situ at presentation and 11 (3%) patients had
suprapubic cystostomy of which only 3 (0.85%) had combined urethral stricture and BPH.
Only 131 (26%) had their PSA measured which ranged from 2–100 ng/ml out of which 39(29.8% n
= 131) patients had more than 4 ng/ml and cancer of the prostate and 1(0.8%, n = 131) patient had
a PSA level of 4 ng/ml and malignant prostate.
Hospital stay was 1–32 days (mean 7.9) and the mean follow up period was 5.6 months (range 0–
60) and there were 17.5% complications comprising of urinary tract infection (UTI) 7.2%, Orchitis
2.2%, urinary incontinence 0.6%, atonic bladder 1%, erectile dysfunction 0.6%, cerebrovascular
accident 0.4%, myocardial infarction 0.4%, deep vein thrombosis 0.4% and disseminated
intravascular coagulopathy (DIC) 0.6% and 1.2% mortality. The cost of treatment inclusive of pre-
admission investigations was US$ 615.00 (range US$ 300–1,300)
Conclusion: Despite advances in minimally invasive therapy for LUTH/BPH, TURP is the optimum
treatment of choice for the ageing male of sub-Saharan Africa. It is however not available to the
majority of patients in this region due to poor health allocation and inadequate facilities and training.
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Background
Benign prostatic hyperplasia (BPH) is the commonest dis-
ease of the urinary tract afflicting the ageing male and is
the commonest tumour in men over the age of 50 years.
Clinically, BPH has been reported to occur in 8% of men
at the age of 40 years rising to 50% and 90% by the ages
of 60 and 80 years respectively [1]. Although reliable data
on the true incidence of prostatic diseases in Northern
Nigeria is lacking, patients with BPH form the bulk of
urology workload in our centre.
Transurethral resection of the prostate (TURP) is the ulti-
mate treatment of choice of BPH, due mainly to the pref-
erence of minimally invasive surgery, long term relief of
symptoms and cost effectiveness. It is however not availa-
ble to the majority of Nigerian patients in need of pros-
tatic surgery in public health institutions, while the high
cost in private hospitals is generally prohibitive.
This paper reviews our experience with TURP in Aminu
Kano Teaching Hospital, Nigeria and examines the pros-
pects of availing the same in other public hospitals despite
limited facilities.
Methods
The records of patients who underwent prostatectomy in
Aminu Kano Teaching Hospital, over the period June
2001 to July 2007 were retrieved and examined. The bio
data of patients, records of pre-operative biochemistry,
haematological and microbiological investigations per-
formed were also retrieved. Mode of clinical presentation,
presence of co-morbidity and its treatment outcome,
recorded clinical findings particularly digital rectal exami-
nation of the prostate, as well as intra- and post-operative
complications and histology of resected prostate chips
were also extracted and noted from the patients' case
notes and Pathology Department Register respectively.
Informed consents were routinely obtained from all the
patients indicating that data recorded in their files could
be used for research purposes. The ethical approval was
given to all retrospective studies due to its being a form of
audit.
Transurethral procedures were carried out by 2 Urological
surgeons. Distilled water at a height of 1 metre from the
bladder (exerting a pressure head of 98 cmH2O) was used
as irrigation fluid and one set of size 27 FG Olympus con-
tinuous flow working sheath with 5° telescopes were used
for resection of all the prostates.
All procedures were abandoned once a capsular perfora-
tion was made and 15 (3%) of such cases were identified.
Excluded were patients who had open prostatectomy and
transurethral bladder neck incisions. SPSS 12.0 was used
for statistical analysis of extracted data.
Results
A total of 542 patients had prostatectomy out of which 40
were excluded due to open prostatectomy (22 cases),
bladder neck stenosis (16 patients) or bladder tumour
around the trigon (2 patients). Five hundred and two
(502) cases were therefore available for analysis.
The age range of the patients was 47–110 years with a
mean of 67.2 ± 9.8 SD (Table 1).
Two hundred and eighty nine patients (80.1%) had a ure-
thral catheter in situ at presentation, and 11 (3%) patients
had suprapubic catheter (SPC) out of which only 3
(0.85%) had combined urethral stricture and BPH, the
others had high riding prostate. Seven patients (1.4%)
were identified to have had chronic urinary retention of
which 3 (0.6%) never recovered detrusor function and
remained with urethral catheter more than a year post-
operatively.
Significant co-morbidity was found in 147 (29.3%)
patients in the form of cardiovascular disease (137
[27.3%] patients), chronic obstructive airway disease (5
[0.99%] patients) and chronic renal failure (5 [0.99%]
patients).
Digital rectal examination revealed benign enlarged pros-
tates in 490(97.6%) patients and 12 (2.4%) patients had
suspicious prostate carcinoma, confirmed on biopsy.
Prostate specific antigen (PSA) assay and transrectal ultra-
sound (TRUS) facilities were not available in AKTH until
late 2003 and 2007 respectively. One hundred and thirty
Table 1: Age distribution (years)
Age Range Number Percentage (%)
45–50 14 (2.8%)
51–55 46 (9.2%)
56–60 86 (17%)
61–65 112 (22.3%)
66–70 116 (23%)
71–75 51 (10.2%)
76–80 46 (9.2%)
81–85 10 (2%)
86–90 11 (2.2%)
91–95 4 (0.8%)
96–100 3 (0.6%)
101–105 3 (0.6%)
106–110 1 (0.2%)
TOTAL 502 100%BMC Urology 2008, 8:18 http://www.biomedcentral.com/1471-2490/8/18
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one (131 [26%]) patients had PSA assay measured (Figure
1). There was no data available on post void residual vol-
ume.
The pre-operative Haemoglobin (Hb) of patients was 5–
17 g/dl (mean 12.7 ± 2.2 SD) and 154(30.7%) patients
with Hb ≤ 10 were transfused pre-operatively. The post
operative transfusion rate for all groups was 0.8%.
Medical treatment in the form of Prazocin 4–8 mg (5
patients, 1%) or alfuzocin 10 mg(8 patients, 1.6%) nocte
were given to only 13 patients(2.6%) and of this 3
patients(0.6%) in Prazocin group opted for TURP due to
intolerable postural hypotension while remaining 2
patients and those in alfuzocin group(totalling 2%) opted
for TURP due to cost consideration long term.
Only 71 patients (14%) had IPSS scored in their files, of
which 18 patients (3.6%) had a mean IPPS of 14 ± 3.81
SD and 53 patients (10.6%) had IPSS of 24 ± 7.71 SD.
Fourteen patients were not scored for IPSS.
Majority of patients (92%) were operated upon under spi-
nal sub-arachnoid block while 6.7% were done under
'saddle' block, using 3 mls of 0.5% bupivacain and 5
patients (1.3%) had general anaesthesia either as conver-
sion (2 patients) or due to sub-arachnoid blockade con-
tra-indications (3 patients).
The amount of prostate chips resected weighed between
3–146 gm (mean 59.8 gm, ± 27.8 SD) over an operation
period of 20–120 minutes (mean 64.1 minutes). There
was no documented TUR syndrome.
Urethral catheters were removed in 0–30 days (mean 3.8,
± 4.6 SD) but 10 patients (2%) needed re-catheterization,
with successful trial without catheter in 7 patients (1.4%)
after 2 weeks. Persistent irritative symptoms were
recorded in 2 patients (0.4%) who did not improve on
medical therapy at one year follow up. Re-operation was
performed in 5 patients 2 years after initial operation due
to intractable haematuria (2 patients, 0.4%), recurrent
adenoma 3 patients (0.6%). All patients had residual
urine measured with a urethral catheter before discharge.
Satisfactory outcome was recorded in the immediate post-
operative period in 483 patients (96.2%).
There were 6 peri-operative deaths (1.2%) in the age
groups 56–60 years (DVT/PE/DIC) and 71–75 years (MI).
The 2 myocardial infarctions occurred intra-operatively
PSA levels by age groups. Figure 1
PSA levels by age groups. Note that all the confirmed carcinoma of the prostate are in the 13.7—100 range.
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from hypotensive episodes and 3 patients (0.8%) had
chronic renal failure due to obstructive uropathy not
resolved by TURP.
Hospital stay was 1–32 days (mean 7.9 ± 5.2 SD) and the
follow up period was 0–60 months, (mean 5.6 ± 8.3 SD).
The average cost of treatment inclusive of pre-admission
work-up investigations was US$300–1,300, (mean
US$617.00 ± 231 SD).
Discussion
Transurethral prostatectomy is still a novel procedure in
most government hospitals in Sub-Saharan Africa due
mainly to non-availability of equipments and inadequate
number of trained personnel conversant with the proce-
dure. Patients' perception of high post-operative morbid-
ity and mortality associated with open prostatectomy in t
he locality makes the majority of them reluctant to present
early for appropriate therapy as evidenced by the large
number presenting with urethral catheter in situ in our
series (83.1%) compared with 24% in North America and
42% in the United Kingdom [2]. The high incidence of
urethral catheterisation is known to be associated with
100% bacteriuria and urinary tract infections (UTI) when
catheter remains in situ for ≥ 4 days [9]. Detected and
treated urinary tract infections resulted in persistent bacte-
riuria in 9.4% of our patients (Table 2), which is lower
than what was reported by Wilson et al (36%) [2,3].
The highest incidence of LUTS/BPH was found in the age
group 56–70 years accounting for a total of 62% of the
patients operated in this study. This correlates similar fig-
ure reported by Garraway et al of 66% [3,4].
Co-morbidity is both a strong predictor of length of stay
and excess risk of death peri-operatively. Co-morbidities
of 29.3% in this study compares favourably to 25% for
open prostatectomy in Sicilian-Calabrian region of Italy
which may suggest similar standards of healthcare in the
2 regions [5].
Water was used as irrigation fluid during resection due to
non-availability of glycine and other irrigation fluids
which were expensive to import. Distilled sterile water is
cheap, available in abundance and safe as irrigation fluid
in transurethral resections and though not proven in this
study, the intravesical pressure was likely to be less than
40 cmH2O which is the critical pressure above which fluid
is significantly absorbed [6-8]. There was no accurate
record on the number of capsular perforations but they
must have occurred in excess of the 15 recorded cases in
this series but without serious consequences as regards
TUR syndrome, haemolysis or significant haemorrhage.
The complication rate of 17.5% and mortality of 1.2% in
this study (Table 3) are rather high, but men presenting
with BPH in retention are known to have an excess risk of
death and increased risk of peri-operative complications.
The mortality rate of 1.2% is higher than that of a larger
series reported by Ansari et al from Victorian Hospitals of
0.8% and the widely accepted mortality rate of 1% associ-
ated with TURP [9]. This may be due to less optimum
back up facilities in our unit and the initial inexperience
in the choice of anaesthetic techniques. 'Saddle' sub-
arachnoids blockade was introduced in 34 patients
(6.7%) in an attempt to reduce the frequently encoun-
tered hypotension due to T10–12  sympathetic ganglion
blockade and none of these suffered similar complica-
tions.
Total blood loss was low with a post operative transfusion
rate of 0.8% which is better than the rate of 8.2% for open
prostatectomy [10-12]. This is an advantage in a society
with high incidence of HIV/AIDS and other viral transmis-
sible infections.
TURP is associated with a post-operative hypercoagulable
state just as in other pelvic surgeries and a deep vein
thrombosis (DVT) of 6.8–10% [13] but most urologists in
the locality are apprehensive of using low molecular
weight heparin despite this. There were 0.4% patients
with DVT in our review ending in fatalities. In spite of this,
Table 2: Urinary microbial isolates in patients with catheter pre-
op.
Urine microbial Pre-operative Post-operative
Escherichia coli 21 (4.2%) 13 (2.6%)
Klebsiella species 20 (4%) 12 (2.4%)
Proteus species 12 (2.4%) 1 (0.2%)
Staphylococcus aureus 17 (3.4%) 10 (2%)
Table 3: Significant peri-operative complications
Complications No. (%) Outcome
Post-operative UTI 36 (7.2%) Treated
Orchitis 11 (2.2%) Resolved
Urine incontinence 3 (0.6%) 2 resolved
Atonic bladder 5 (1%) 3 resolved
Erectile Dysfunction 3 (0.6%) Permanent
Cerebrovascular Accident 2 (0.4%) 2 Recovered
Myocardial Infarction 2 (0.4%) 2 died
DVT/PE 2 (0.4%) 2 died
DIC 3 (0.6%) 2 died
TOTAL 57 (13.4%) 9 (1.8%) permanent
Key: 
DVT: Deep Vein Thrombosis
PE: Pulmonary Embolism
DIC: Disseminated Intravascular CoagulopathyBMC Urology 2008, 8:18 http://www.biomedcentral.com/1471-2490/8/18
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only physical measures and clotting profile assays were
employed to reduce the risk of DVT and pulmonary
embolism.
Incidental adenocarcinoma of the prostate of 5.6% (Table
4) is much lower than was found by Dawam (10%) in
Zaria [14], due to better assessment by combining digital
rectal examination with quantitative prostate specific anti-
gen assay and transrectal ultrasound.
The predictors of length of stay are: intrinsic patient fac-
tors such as co-morbidities, advances in peri-operative
care and surgical techniques and extrinsic hospital factors
such as resources, capacity and efficient bed management
[15]. The length of stay in our study was governed by defi-
ciencies in all of the above factors. Lack of updated equip-
ments and skilled manpower coupled with patients with
multiple co-morbidities was the usual scenario. We were
able to show positive correlation between co-morbidities
and length of stay in this study (Pearson's correlation
0.233, p ≥ 0.01).
Impotence is reported to occur, in the literature in 11% of
cases post-TURP, but only 0.6% was picked up in this
study due to incomplete information, which is one of the
draw backs of retrospective study.
The cost of treatment is rather high for an average Nige-
rian as the gross domestic product (GDP) per capita of
US$800 is low even within Africa, coupled with poor
health allocation from the Budget (2.6%) [16].
Conclusion
The morbidity and mortality of TURP is expectedly higher
than what is obtained internationally, but still lower than
what was found following open prostatectomy even in
European series. The overall cost of TURP was high for an
average Nigerian considering the per capita income of
US$800:00 but was worthwhile in view of its inherent
minimal trauma, short hospital stay and early recovery.
Despite advances in minimally invasive therapy for lower
urinary tract symptoms/BPH, TURP is the optimum treat-
ment of choice for BPH in the ageing male population of
sub-Saharan Africa, but better facilities and skilled medi-
cal staff are needed to make it safer and affordable for the
majority of patients in public health institutions.
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